Group 1 - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [4] - The company is advancing verekitug, a monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), which is involved in inflammatory responses [4] - The Phase 2 VIBRANT trial is designed to evaluate the efficacy and safety of verekitug in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) [2] Group 2 - The VIBRANT trial is a global, randomized, placebo-controlled study where participants receive either 100 mg of verekitug or a placebo every 12 weeks for 24 weeks [2] - The primary endpoint of the trial is the change in endoscopic nasal polyp score (NPS) at Week 24 [2] - Top-line data from the VIBRANT trial will be reported on September 2, 2025, during a conference call and webcast [1][3]